Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer Academic Article Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Biomarkers, Tumor
  • Genomic Instability
  • Pancreatic Neoplasms
  • Precision Medicine

abstract

  • No major activity was observed in a population of previously treated patients. Ninety-six-hour paclitaxel in metastatic esophageal cancer is generally well tolerated with minimal toxicity; however, it is ineffective in previously treated patients. Further evaluation of this schedule of paclitaxel in combination with concurrent radiotherapy, where its radiosensitizing potential may be useful, is ongoing in locally advanced esophageal cancer.

publication date

  • October 6, 2003

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1081/CNV-120022360

PubMed ID

  • 14533440

Additional Document Info

start page

  • 512

end page

  • 6

volume

  • 21

number

  • 4